-
Sector Analysis
NewXylene Industry Capacity and Capital Expenditure Forecasts with Details of All Active and Planned Plants to 2028
Global xylene capacity is poised to see considerable growth, potentially increasing from 93.49 million tonnes per annum (mtpa) in 2023 to 108.94 mtpa in 2028. Most of the xylene capacity additions are primarily expected in Asia and the Middle East.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Nomacopan in Thrombotic Microangiopathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Nomacopan in Thrombotic Microangiopathy report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Nomacopan in Thrombotic Microangiopathy Drug Details: Nomacopan is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Onabotulinumtoxin A in Myofascial Pain Syndrome (Chronic Myofascial Pain)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onabotulinumtoxin A in Myofascial Pain Syndrome (Chronic Myofascial Pain) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Onabotulinumtoxin A in Myofascial Pain Syndrome...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BP-1002 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Cutaneous T-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BP-1002 in Cutaneous T-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Cutaneous T-Cell Lymphoma Drug Details: BP-1002 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BP-1002 in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Peripheral T-Cell Lymphomas (PTCL) Drug Details: BP-1002...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Cobolimab in Hepatocellular Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Cobolimab in Hepatocellular Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Cobolimab in Hepatocellular Carcinoma Drug Details: Cobolimab is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BP-1002 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Relapsed Acute Myeloid Leukemia Drug Details: BP-1002...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BP-1002 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Refractory Acute Myeloid Leukemia Drug Details: BP-1002...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avdoralimab in Bullous Pemphigoid
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avdoralimab in Bullous Pemphigoid report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Avdoralimab in Bullous Pemphigoid Drug Details: Avdoralimab (IPH-5401) is under development...